Warning: Invalid argument supplied for foreach() in /home/dheesqdo/public_html/wp-content/plugins/smart-blocks/inc/generate-css.php on line 252
Warning: Invalid argument supplied for foreach() in /home/dheesqdo/public_html/wp-content/plugins/smart-blocks/inc/generate-css.php on line 46
10″ Aug” 2022
Dabaysha Covid-19 ayaa kor u qaadday sawirka dakhliga kororka muddada-dheer ee shirkadaha Pfizer iyo Moderna oo raaci doona xeelado iska soo horjeeda marka ay dhamaato baahida loo qabo talaalada Corona Virus
Pfizer waxa ay isku dayaysaa in ay ku darto $25 bilyan dakhligeeda 2030 iyada oo la iibsanayo.
Pfizer PFE –0.43% ‘s $5.4 bilyan heshiiska si ay u hesho biotech Global Blood Therapeutics ayaa sii socotay hal sano oo $26.4 bilyan wax iibsiga ah, iyada oo shirkaddu ay dabaysha Covid-19 ka dhigayso in ay kor u qaaddo sawirka dakhliga muddada-dheer.
Ololaha M&A ee uu qaado Pfizer (Ticker: PFE) waxa uu u taagan yahay istraatijiyad ka duwan istiraatijiyadda ay xafiiltamaan Moderna MRNA +0.32% (MRNA), taas oo aan ilaa hadda wax M&A ah samayn, taa beddelkeedana ay ku kharash garayso lacagteeda ‘Covid-19’ kaashkeeda dhuumaha iyo kaydkeeda. dib u gadasho.
Ilaa hadda, maalgashadayaasha waxay u muuqdaan kuwo aad ugu qanacsan habka Pfizer. Saamiyada Pfizer ayaa kor u kacay 11.3% 12-kii bilood ee la soo dhaafay, halka saamiyada Moderna ay hoos u dhaceen 62.2%. S&P 500 SPX +1.94% ayaa hoos u dhacay 5.2% wakhtigaas.
Istaraatiijiyadda Pfizer waxay u ekaan kartaa mid caqli badan. Laakiin haddii Moderna ay shaqeyso, wax-soo-saarku wuxuu noqon karaa mid la taaban karo.
Labada shirkadoodba waxay wajahayaan hoos u dhac dakhliga tallaalka Covid-19. Falanqeeyayaasha ayaa filayaa in iibinta tallaalka Covid-19 uu ku dhawaad kala bar ka dhici doono labada shirkadood inta u dhaxaysa 2022 iyo 2023. Baahida ayaa durba u muuqata inay hoos u dhacayso: Talaadada, soo saaraha tallaalka Covid-19 Novavax NVAX –0.07% (NVAX) ayaa si weyn u dhimay hagitaankeedii dakhliga 2022.
Marka laga soo tago hoos u dhaca iibka tallaalka Covid-19, si kastaba ha ahaatee, Pfizer iyo Moderna waxay la kulmaan cadaadisyo kala duwan.
Moderna wali waxay u baahan tahay inay caddayso dulucda ay soo bandhigtay tan iyo markii la aasaasay 2010: In madalkeeda mRNA ay si dhakhso ah u soo saari karto dawooyin kala duwan. Ilaa hadda madal waxa ay soo saartay hal dawo oo keliya; mid ka mid ah dawooyinka ugu iibsiga badan taariikhda, waa hubaal, laakiin mid aan la hubin mustaqbalkiisa.
Pfizer, dhanka kale, waxa ay wajahaysaa Shirkaddu waxay ka shaqaynaysay sanado badan si ay u xaqiijiso maalgashadayaasha in ay sii wadi karto kor u qaadida dakhliga inkasta oo kuwa soo socda ay luminayaan gaar ahaan; Walaacaas ayaa kaydka ka dhigay mid dhulka xad dhaaf ah xitaa iyadoo iibka tallaalkiisa Covid-19 uu cirka isku shareeray sanadka 2021.
Furaha dammaanaddaas waa Istaraatiijiyadda M&A ee Pfizer, oo ay sheegtay in looga golleeyahay in lagu daro $25 bilyan dakhligeeda 2030.
Dhammaan Pfizer’s M&A, Moderna waxay ku fadhiisatay gacmaheeda. “Maalgashadayaashu ma rabaan inaan samayno wax waalan,” Maamulaha Moderna Stéphane Bancel ayaa u sheegay Barron’s usbuucii hore.
Moderna waxay sheegtay usbuucii hore inay haysato $18.1 bilyan oo kaash ah iyo lacag caddaan ah ilaa dhammaadka Juun. Waxay ku kharash garaysay $1.3 bilyan dib-u-soo-celinta saamiyada rubuci labaad, waxay billowday $3 bilyan barnaamij dib-u-iibsasho wadaag ah, waxayna haysataa $1 bilyan oo ka hartay awoodda dib-u-iibsashada ee barnaamij hore loo oggolaaday. Dhanka kale, shirkaddu waxay sheegtay inay cilmi-baarista iyo horumarinta ku bixisay $1.3 bilyan qeybtii hore ee sannadka.
“Waxay rabaan inaan abuurno qiime,” ayuu Bancel u sheegay Barron’s. “Marka aad ayaan ugu faraxsanahay markaan u sheegno inay eegaan, waxaan ku celineynaa lacag caddaan ah saamileyda, sababtoo ah rubuci ugu dambeeyay ma helin wax aan sameyno. Ma dooneyno inaan sameyno wax weyn aawadood inaan sameyno heshiis weyn. “
Bancel waxa uu sheegay in uu doonayo in shirkadu ay diirada saarto dhuumaha balaadhan ee ay leedahay, kaas oo hadda ku jira afar barnaamij oo ku jira tijaabada Wajiga 3 iyo saddex kale oo ku jira tijaabada Wajiga 2. “Maxaynu, marxaladdan ciyaarta ku jirta, u doonaynaa inaan samayno wax kale oo dhalaalaya, marka aan aad ugu dhownahay hantidayada cajiibka ah,” ayuu Bancel u sheegay Barron’s.
Kalsoonida Bacel ee dhuuntiisa ayaa wali u baahan in lagu soo bandhigo tijaabooyinka socda ee shirkadda, laakiin xagaagan, maalgashadayaasha ayaa muujiyay calaamad muujinaysa wadaagista iimaanka Bacel. Inkasta oo saamiyadu ay wali si fiican uga hooseeyaan heerkii ugu sarreeyay ee sannadkii hore, waxay kor u kacday 22% tan iyo bilowgii Juun.
